Icahn Speculation Around Valeant (VRX) Grows Following Interview
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Pennsylvania measles cases near 800 as outbreak grows
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- A timeline of Trump administration moves to weaken endangered species protections
Valeant Pharma (VRX) At Lows Into the Close
November 4, 2015 3:43 PM ESTValeant Pharma (NYSE: VRX) is trading near the lows into the close. Shares are down 6% to $92. Today's senate hearing on drug pricing, the 'missing piece' hit piece and reports from Reuters that OptumRx caught on to odd billing at Valeant-linked pharmacy more than a year ago, are all weighting.
... More